Bedrijfsoverzicht
Personalis, Inc. is a specialized entity within the healthcare sector, specifically operating in the diagnostics and research industry where it focuses on the development, marketing, and sale of advanced cancer genomic tests and services for both domestic and international markets. The company's primary product offering includes NeXT Personal, a tumor-informed liquid biopsy test designed to detect minimal residual disease, monitor therapy response, and track disease recurrence in solid tumors. In terms of scale, the company holds a market capitalization of $630.16M and reported total annual revenue of $69.65M over the trailing twelve months, while employing a workforce of 259 individuals. These financial figures indicate that Personalis operates as a mid-sized enterprise with a significant market capitalization relative to its current revenue stream, suggesting a valuation that the market places a premium on future potential rather than current profitability, a common characteristic in biotechnology firms investing heavily in research and development.
Financiële gezondheid
The company reported a revenue of $69.65M, yet this generated a net income of -$81,270,000 and an EBITDA of -$78,011,000, revealing a substantial gap between top-line generation and bottom-line profitability that highlights an aggressive cost structure or significant one-time expenses impacting the bottom line. The free cash flow stands at -$42,980,752, which indicates that the company is currently burning cash and relies on existing liquidity reserves to fund operations and capital expenditures without external financing. Analyzing the three key margin metrics, the gross margin is 22.7%, indicating a moderate ability to cover the direct costs of producing genomic tests, while the operating margin of -145.7% and profit margin of -116.7% demonstrate severe operational inefficiencies or high overhead costs that are eroding all gross profits. The balance sheet shows a robust cash position of $239.95M against total debt of $44.01M, resulting in a debt-to-equity ratio of 16.85, which suggests a balance sheet that is heavily reliant on equity financing rather than leverage, though the high debt-to-equity figure technically flags a leveraged structure in traditional terms despite the absolute cash surplus. The current ratio is 6.76, a figure that signifies extremely strong short-term liquidity, providing ample coverage for current liabilities and ensuring the ability to meet operational obligations. Furthermore, the return on equity is -35.0% and the return on assets is -18.2%, metrics that reveal that management is currently generating negative returns on shareholder capital and the total asset base, reflecting the losses incurred during the reporting period.
Waarderingsbeoordeling
The valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to the net loss, while the forward P/E is -6.45, implying that analysts or the market expects earnings to remain negative in the immediate future or that the current negative earnings trajectory is priced in. The price-to-book ratio is 2.36, which indicates that the market is valuing the company at more than double its book value, suggesting a belief in intangible assets or future growth potential that exceeds the net asset value recorded on the balance sheet. Alternative valuation multiples such as the price-to-sales ratio of 9.05 and the EV/EBITDA of -5.56 suggest that the market is pricing the stock based on revenue generation rather than earnings, as the negative EV/EBITDA reinforces the current loss-making status. Regarding price volatility and range, the stock has a 52-week high of $11.50 and a 52-week low of $3.09, meaning the current share price sits significantly below the yearly peak and is trading within the lower end of its historical trading range, reflecting the uncertainty surrounding the company's path to profitability. The beta value is 2.21, which indicates that the stock's price volatility is more than twice that of the broader market, exposing investors to higher risk fluctuations in response to market movements or sector-specific news.
Growth & Income
Personalis, Inc. demonstrated a revenue growth rate of 3.2% year-over-year, while earnings growth is listed as N/A due to the company's net losses, implying that top-line expansion is occurring without corresponding improvement in profitability, a typical phase for clinical-stage or early-commercial biotechnology companies. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that the firm retains all of its earnings to reinvest in research, development, and commercialization efforts rather than distributing income to shareholders. Because the company is not a dividend payer, the 0.0% payout ratio is inherently sustainable as it reflects a strategic decision to fund operations and growth initiatives through cash reserves rather than shareholder distributions. Overall, the growth and income profile is characterized by steady single-digit revenue expansion paired with significant cash burn, relying entirely on capital markets or internal cash reserves to bridge the gap until the company achieves positive earnings.